Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), bought 15,000 shares at $52.40 ($788K) on 2017-08-28, disclosed to the SEC on 2017-08-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.40 | 5,853 | $307K | 38.9% |
| 2 | $52.40 | 5,853 | $307K | 38.9% |
| 3 | $52.96 | 1,647 | $87K | 11.1% |
| 4 | $52.96 | 1,647 | $87K | 11.1% |
| Total | $52.52 avg | 15,000 | $788K | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |